Morgan Stanley analyst Vikram Purohit lowered the firm’s price target on Legend Biotech (LEGN) to $80 from $82 and keeps an Overweight rating on the shares. The firm updated its model to reflect quarter-over-quarter trends anticipated for Carvykti in 2025 and to moderate its 2025-plus ex-U.S. Carvykti ramp expectations.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech (LEGN) Blockbuster Fuels Expectation-beating Growth
- Legend Biotech’s Earnings Call: Growth and Expansion
- Strong Buy Rating for Legend Biotech Driven by Carvykti’s Exceptional Growth and Competitive Edge
- Legend Biotech’s Growth Potential: Buy Rating Backed by Manufacturing Expansion and Safety Enhancements
- Legend Biotech: Strong Sales and Strategic Focus Drive Buy Rating
Questions or Comments about the article? Write to editor@tipranks.com